In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: No two opioids have the same profile

British Journal of Pharmacology

Volumn 172, Issue 2, 2015, Pages 532-548

  Kuo, A ^a   Wyse, B D ^a   Meutermans, W ^b   Smith, M T ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Alchemia Pty Ltd   (Australia)

Author keywords

antinociception; buprenorphine; constipation; fentanyl; intracerebroventricular; morphine; morphine 6 glucuronide (M6G); oxycodone; rat; respiratory depression

Indexed keywords

BUPRENORPHINE; FENTANYL; MORPHINE; MORPHINE 6 GLUCURONIDE; OPIATE; OXYCODONE; BENZENEACETAMIDE DERIVATIVE; CASTOR OIL; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; MORPHINE DERIVATIVE; MORPHINE-6-GLUCURONIDE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NARCOTIC ANALGESIC AGENT; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; IN VIVO STUDY; MALE; NONHUMAN; PLETHYSMOGRAPHY; RAT; RESPIRATION DEPRESSION; TAIL FLICK TEST; ANIMAL; CHEMICALLY INDUCED; COMPARATIVE STUDY; HEAT; PAIN; PATHOPHYSIOLOGY; RESPIRATORY FAILURE; SPRAGUE DAWLEY RAT;

ANALGESICS, OPIOID; ANIMALS; BENZENEACETAMIDES; BUPRENORPHINE; CASTOR OIL; CONSTIPATION; DIARRHEA; ENKEPHALIN, D-PENICILLAMINE (2,5)-; FENTANYL; HOT TEMPERATURE; MALE; MORPHINE; MORPHINE DERIVATIVES; OXYCODONE; PAIN; PYRROLIDINES; RATS, SPRAGUE-DAWLEY; RESPIRATORY INSUFFICIENCY;

EID: 84920119640     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12696     Document Type: Article

References (77)

1. Abbott FV, Palmour RM, (1988). Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats. Life Sci 43: 1685-1695.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
3. Backlund M, Lindgren L, Kajimoto Y, Rosenberg PH, (1997). Comparison of epidural morphine and oxycodone for pain after abdominal surgery. J Clin Anesth 9: 30-35.
4. Blond S, Guieu JD, Meynadier J, Le Bars D, Willer JC, (1994). Intracerebroventricular morphine, analgesia, and nociceptive spinal reflexes. Lancet 343: 857-858.
5. Bourasset F, Cisternino S, Temsamani J, Scherrmann JM, (2003). Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. J Neurochem 86: 1564-1567.
6. Broccardo M, Improta G, (1992). Antidiarrheal and colonic antipropulsive effects of spinal and supraspinal administration of the natural delta opioid receptor agonist, [D-Ala2]deltorphin II, in the rat. Eur J Pharmacol 218: 69-73.
7. Brown SM, Holtzman M, Kim T, Kharasch ED, (2011). Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 115: 1251-1260.
8. Bui JD, Nammari DR, Buckley DL, Inglis BA, Silver XS, Mareci TH, et al. (1999). In vivo dynamics and distribution of intracerebroventricularly administered gadodiamide, visualized by magnetic resonance imaging. Neuroscience 90: 1115-1122.
9. Burks TF, Fox DA, Hirning LD, Shook JE, Porreca F, (1988). Regulation of gastrointestinal function by multiple opioid receptors. Life Sci 43: 2177-2181.
10. Butelman ER, France CP, Woods JH, (1993). Apparent pA2 analysis on the respiratory depressant effects of alfentanil, etonitazene, ethylketocyclazocine (EKC) and Mr2033 in rhesus monkeys. J Pharmacol Exp Ther 264: 145-151.
11. Carrupt PA, Testa B, Bechalany A, el Tayar N, Descas P, Perrissoud D, (1991). Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. J Med Chem 34: 1272-1275.
12. Chung S, Pohl S, Zeng J, Civelli O, Reinscheid RK, (2006). Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance. J Pharmacol Exp Ther 318: 262-267.
13. Cox BM, Christie MJ, Devi L, Toll L, Traynor JR, (2015). Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br J Pharmacol 172: 317-323.
14. Dahan A, (2006). Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med 20 (Suppl. 1): s3-s8.
15. Dietis N, Rowbotham DJ, Lambert DG, (2011). Opioid receptor subtypes: fact or artifact? Br J Anaesth 107: 8-18.
16. Ferrante FM, (1996). Principles of opioid pharmacotherapy: practical implications of basic mechanisms. J Pain Symptom Manage 11: 265-273.
17. Francisco NA, (2007). Control of breathing: how to better understand the respiratory effects of opioids. Eur J Pain (Suppl. 1): 61-65.
18. Furst S, Riba P, Friedmann T, Timar J, Al-Khrasani M, Obara I, et al. (2005). Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat. J Pharmacol Exp Ther 312: 609-618.
19. Galligan JJ, Burks TF, (1983). Centrally mediated inhibition of small intestinal transit and motility by morphine in the rat. J Pharmacol Exp Ther 226: 356-361.
20. Goineau S, Rompion S, Guillaume P, Picard S, (2010). Ventilatory function assessment in safety pharmacology: optimization of rodent studies using normocapnic or hypercapnic conditions. Toxicol Appl Pharmacol 247: 191-197.
21. Greer JJ, Smith JC, Feldman JL, (1991). Role of excitatory amino acids in the generation and transmission of respiratory drive in neonatal rat. J Physiol 437: 727-749.
22. Hindle A, (2008). Intrathecal opioids in the management of acute postoperative pain. Contin Educ Anaesth Crit Care Pain 8: 81-85.
23. Hjelmstad GO, Fields HL, (2003). Kappa opioid receptor activation in the nucleus accumbens inhibits glutamate and GABA release through different mechanisms. J Neurophysiol 89: 2389-2395.
24. van den Hoogen RH, Colpaert FC, (1986). Respiratory effects of morphine in awake unrestrained rats. J Pharmacol Exp Ther 237: 252-259.
25. Jaffe JH, Martin WR, (1991). Opioid analgesics and antagonists. In:, Goodman Gilman A, Rall TW, Nies AS, Taylor P, (eds). In the Pharmacological Basis of Therapeutics, 8th edn. Pergamon Press: New York, pp. 485-521.
26. Jordan BA, Devi LA, (1999). G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399: 697-700.
27. Katsumata S, Minami M, Nakagawa T, Iwamura T, Satoh M, (1995). Pharmacological study of dihydroetorphine in cloned mu-, delta- and kappa-opioid receptors. Eur J Pharmacol 291: 367-373.
28. Kelly E, (2013). Efficacy and ligand bias at the mu-opioid receptor. Br J Pharmacol 169: 1430-1446.
29. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
30. Koo CY, Eikermann M, (2011). Respiratory effects of opioids in perioperative medicine. Open Anesthesiol J 5: 23-34.
31. La Regina A, Petrillo P, Sbacchi M, Tavani A, (1988). Interaction of U-69 593 with mu-, alpha- and kappa-opioid binding sites and its analgesic and intestinal effects in rats. Life Sci 42: 293-301.
32. Lahti RA, Mickelson MM, McCall JM, Von Voigtlander PF, (1985). 3H]U-69593 a highly selective ligand for the opioid kappa receptor. Eur J Pharmacol 109: 281-284.
33. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD, (2006). Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79: 461-479.
34. Law PY, Reggio PH, Loh HH, (2013). Opioid receptors: toward separation of analgesic from undesirable effects. Trends Biochem Sci 38: 275-282.
35. Lee KO, Akil H, Woods JH, Traynor JR, (1999). Differential binding properties of oripavines at cloned mu- and delta-opioid receptors. Eur J Pharmacol 378: 323-330.
36. Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER, et al. (2006). Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology 105: 801-812.
37. Leow KP, Smith MT, (1994). The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sci 54: 1229-1236.
38. Levinger IM, (1971). The cerebral ventricles of the rat. J Anat 108 (Pt 3): 447-451.
39. Ling GS, Spiegel K, Lockhart SH, Pasternak GW, (1985). Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J Pharmacol Exp Ther 232: 149-155.
40. Luger TJ, Kathrein A, Rieger M, Lorenz IH, (2005). Intracerebroventricular and intrathecal injectate spread in rats. Eur J Anaesthesiol 22: 236-239.
41. Massi P, Giagnoni G, Basilico L, Gori E, Rubino T, Parolaro D, (1994). Intestinal effect of morphine 6-glucuronide: in vivo and in vitro characterization. Eur J Pharmacol 253: 269-274.
42. Mather LE, Smith MT, (1999). Clinical pharmacology and adverse effects. In:, Stein C, (ed.). Opioids in Pain Control: Basic and Clinical Aspects, 1st edn. Cambridge University Press: Cambridge, NJ, pp. 188-211.
43. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
44. McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, et al. (2010). μ-Opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 78: 756-766.
45. Meert TF, Vermeirsch HA, (2005). A preclinical comparison between different opioids: antinociceptive versus adverse effects. Pharmacol Biochem Behav 80: 309-326.
46. Misra A, Ganesh S, Shahiwala A, Shah SP, (2003). Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 6: 252-273.
47. Molinari P, Vezzi V, Sbraccia M, Gro C, Riitano D, Ambrosio C, et al. (2010). Morphine-like opiates selectively antagonize receptor-arrestin interactions. J Biol Chem 285: 12522-12535.
48. Mutolo D, Bongianni F, Einum J, Dubuc R, Pantaleo T, (2007). Opioid-induced depression in the lamprey respiratory network. Neuroscience 150: 720-729.
49. Nielsen CK, Ross FB, Smith MT, (2000). Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the Dark Agouti rat. J Pharmacol Exp Ther 295: 91-99.
50. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT, (2007). Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 132: 289-300.
51. Ohtani M, Kotaki H, Sawada Y, Iga T, (1995). Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 272: 505-510.
52. Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T, (1997). Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 281: 428-433.
53. Osinski MA, Bass P, Gaumnitz EA, (1999). Peripheral and central actions of orphanin FQ (nociceptin) on murine colon. Am J Physiol 276 (1 Pt 1): G125-G131.
54. Otis JA, (1999). Treatment options for the elderly patient with severe pain. Consultant Pharmacist 14: 19-28.
55. Pazos A, Florez J, (1983). Interaction of naloxone with mu- and delta-opioid agonists on the respiration of rats. Eur J Pharmacol 87: 309-314.
56. Petrillo P, Gambino MC, Tavani A, (1984). Bremazocine induces antinociception, but prevents opioid-induced constipation and catatonia in rats and precipitates withdrawal in morphine-dependent rats. Life Sci 35: 917-927.
57. Pham T, Carrega L, Sauze N, Fund-Saunier O, Devaux C, Peragut JC, et al. (2003). Supraspinal antinociceptive effects of mu and delta agonists involve modulation of adenosine uptake. Anesthesiology 98: 459-464.
58. Plummer JL, Cmielewski PL, Reynolds GD, Gourlay GK, Cherry DA, (1990). Influence of polarity on dose-response relationships of intrathecal opioids in rats. Pain 40: 339-347.
59. Porreca F, Mosberg HI, Hurst R, Hruby VJ, Burks TF, (1984). Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 230: 341-348.
60. Poyhia R, Seppala T, (1994). Liposolubility and protein binding of oxycodone in vitro. Pharmacol Toxicol 74: 23-27.
61. Raehal KM, Walker JK, Bohn LM, (2005). Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 314: 1195-1201.
62. Reisine T, Pasternak GW, (1996). Opioid analgesics and antagonists. In:, Hardman JG, Limbird LE, Molinoff RW, Gilamn AG, (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. McGraw-Hill.: New York, pp. 521-556.
63. Riviere PJ, (2004). Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol 141: 1331-1334.
64. Romberg R, Sarton E, Teppema L, Matthes HW, Kieffer BL, Dahan A, (2003). Comparison of morphine-6-glucuronide and morphine on respiratory depressant and antinociceptive responses in wild type and mu-opioid receptor deficient mice. Br J Anaesth 91: 862-870.
65. Romer D, Buscher H, Hill RC, Maurer R, Petcher TJ, Welle HB, et al. (1980). Bremazocine: a potent, long-acting opiate kappa-agonist. Life Sci 27: 971-978.
66. Ross FB, Smith MT, (1997). The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 73: 151-157.
67. Schug SA, Zech D, Grond S, (1992). Adverse effects of systemic opioid analgesics. Drug Saf 7: 200-213.
68. Shook JE, Lemcke PK, Gehrig CA, Hruby VJ, Burks TF, (1989). Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation. J Pharmacol Exp Ther 249: 83-90.
69. Smith MT, (2008). Differences between and combinations of opioids re-visited. Curr Opin Anaesthesiol 21: 596-601.
70. Smith MT, Wright AW, Williams BE, Stuart G, Cramond T, (1999). Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management. Anesth Analg 88: 109-116.
71. South SM, Wright AW, Lau M, Mather LE, Smith MT, (2001). Sex-related differences in antinociception and tolerance development following chronic intravenous infusion of morphine in the rat: modulatory role of testosterone via morphine clearance. J Pharmacol Exp Ther 297: 446-457.
72. Taniguchi H, Yomota E, Nogi K, Onoda Y, Ikezawa K, (1998). The effect of nociceptin, an endogenous ligand for the ORL1 receptor, on rat colonic contraction and transit. Eur J Pharmacol 353: 265-271.
73. Thorpe DM, (2001). Management of opioid-induced constipation. Curr Pain Headache Rep 5: 237-240.
74. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, et al. (1998). Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178: 440-466.
75. Varamini P, Mansfeld FM, Blanchfield JT, Wyse BD, Smith MT, Toth I, (2012). Synthesis and biological evaluation of an orally active glycosylated endomorphin-1. J Med Chem 55: 5859-5867.
76. Wright AW, Watt JA, Kennedy M, Cramond T, Smith MT, (1994). Quantitation of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in plasma and cerebrospinal fluid using solid-phase extraction and high-performance liquid chromatography with electrochemical detection. Ther Drug Monit 16: 200-208.
77. Yamada KA, Hamosh P, Gillis RA, (1981). Respiratory depression produced by activation of GABA receptors in hindbrain of cat. J Appl Physiol 51: 1278-1286.